Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989，NSC-2260804

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Cited by 130 Publications

Cancer Cell, 2019, 35(4):664-676

PubMed: 30991026 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):46-63

PubMed: 30581152 ( click the link to review the publication )

Nature, 2016, 539(7629):437-442

PubMed: 27642729 ( click the link to review the publication )

Nature, 2016, 532(7599):389-93

PubMed: 27064903 ( click the link to review the publication )

Nat Genet, 2014, 46(4):364-70

PubMed: 24584072 ( click the link to review the publication )

Cancer Cell, 2011, 19(6):792-804

PubMed: 21620777 ( click the link to review the publication )

Cell, 2019, 176(6):1379-1392

PubMed: 30773315 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI124590

PubMed: 30830877 ( click the link to review the publication )

Autophagy, 2019, 15(6):1100-1111

PubMed: 30654687 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1606647

PubMed: 31007149 ( click the link to review the publication )

Leukemia, 2019, 33(1):181-190

PubMed: 29884903 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz073

PubMed: 31002307 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(9):1282-1297

PubMed: 30767208 ( click the link to review the publication )

Am J Transplant, 2019, 19(5):1305-1314

PubMed: 30549430 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5322

PubMed: 31257577 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):77

PubMed: 31315616 ( click the link to review the publication )

J Antimicrob Chemother, 2019, 74(7):1921-1927

PubMed: 30934052 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):118

PubMed: 30987681 ( click the link to review the publication )

Xenotransplantation, 2019, 10.1111/xen.12522

PubMed: 31077480 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):41

PubMed: 30670079 ( click the link to review the publication )

J Immunol, 2019, 202(1):31-36

PubMed: 30518568 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2019, 169:266-272

PubMed: 30453174 ( click the link to review the publication )
J Cell Physiol, 2019, 234(7):12019-12028

PubMed: 30523643 ( click the link to review the publication )

Neurobiol Aging, 2019, 79:30-42

PubMed: 31026620 ( click the link to review the publication )

Front Cell Neurosci, 2019, 10.3389/fncel.2018.00515

PubMed: 30692914 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9805

PubMed: 31285446 ( click the link to review the publication )

JPEN J Parenter Enteral Nutr, 2019, 43(1):96-106

PubMed: 29761871 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(4):882-894

PubMed: 30906218 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108911

PubMed: 31079001 ( click the link to review the publication )

Mol Cell Endocrinol, 2019, 485:72-80

PubMed: 30735697 ( click the link to review the publication )

Cell Signal, 2019, 53:327-338

PubMed: 30389500 ( click the link to review the publication )

Life Sci, 2019, 217:243-250

PubMed: 30550889 ( click the link to review the publication )

J Cell Biochem, 2019, 120(3):3637-3650

PubMed: 30242894 ( click the link to review the publication )

Chem Biol Interact, 2019, 300:18-26

PubMed: 30611790 ( click the link to review the publication )

Am J Transl Res, 2019, 11(2):931-941

PubMed: 30899392 ( click the link to review the publication )

Am J Transl Res, 2019, 11(3):1616-1625

PubMed: 30972187 ( click the link to review the publication )

Am J Transl Res, 2019, 11(3):1473-1485

PubMed: 30972175 ( click the link to review the publication )

Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Drug Des Devel Ther, 2019, 13:1221-1231

PubMed: 31114162 ( click the link to review the publication )

Int J Mol Med, 2019, 44(2):457-468

PubMed: 31173197 ( click the link to review the publication )

Biosci Rep, 2019, 39(5)

PubMed: 29187584 ( click the link to review the publication )

Biosci Rep, 2019, 39(4)

PubMed: 30923227 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

Immunobiology, 2019, 224(3):455-461

PubMed: 30773287 ( click the link to review the publication )

Neurochem Res, 2019, 44(5):1090-1100

PubMed: 30712242 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:5003-5012

PubMed: 31303760 ( click the link to review the publication )
Exp Dermatol, 2019, 28(3):270-275

PubMed: 30650200 ( click the link to review the publication )

Connect Tissue Res, 2019, 10.1080/03008207

PubMed: 30782019 ( click the link to review the publication )

Animal, 2019, 10.1017/S1751731118003683

PubMed: 30616697 ( click the link to review the publication )

Mol Med Rep, 2019, 20(2):1523-1530

PubMed: 31257459 ( click the link to review the publication )

Med Sci Monit, 2019, 25:5389-5400

PubMed: 31325378 ( click the link to review the publication )

J Gynecol Obstet Hum Reprod, 2019, 48(3):193-199

PubMed: 30553049 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

Int J Cancer, 2018, 142(1):202-213

PubMed: 28905990 ( click the link to review the publication )

Cancer Lett, 2018, 436:28-37

PubMed: 30118842 ( click the link to review the publication )

Arch Toxicol, 2018, 92(10):3163-3173

PubMed: 30132043 ( click the link to review the publication )

FASEB J, 2018, 32(10):5602-5611

PubMed: 29718710 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(1):54-62

PubMed: 29996117 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2091-2099

PubMed: 30045927 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(6):1259-1270

PubMed: 29545332 ( click the link to review the publication )

J Mol Med (Berl), 2018, 96(8):807-817

PubMed: 29959473 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386287 ( click the link to review the publication )

J Dermatol Sci, 2018, 92(2):172-180

PubMed: 30220530 ( click the link to review the publication )

J Cell Biochem, 2018, 10.1002/jcb.27481

PubMed: 30206977 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Neurol Res, 2018, 10.1080/01616412

PubMed: 30325723 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.23525

PubMed: 28524818 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.150

PubMed: 27132509 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )
Mol Cell Biol, 2016, 36(10):1555-68

PubMed: 26976639 ( click the link to review the publication )

Acta Pharmacol Sin, 2016, 10.1038/aps.2016.31

PubMed: 27264314 ( click the link to review the publication )

Cell Signal, 2016, 28(8):1086-98

PubMed: 27185187 ( click the link to review the publication )

World J Gastroenterol, 2016, 22(18):4501-14

PubMed: 27182160 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

J Hepatol, 2015, 10.1016/j.jhep.2015.11.011

PubMed: 26592953 ( click the link to review the publication )

Autophagy, 2015, 10.1080/15548627.2015.1023982

PubMed: 25906440 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.01.014

PubMed: 25660019 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

Oncogene, 2015, 34(2):263-8

PubMed: ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.226

PubMed: 26165839 ( click the link to review the publication )

Cancer Lett, 2015, 357(2):468-75

PubMed: 25444920 ( click the link to review the publication )

J Pathol, 2015, 235(5):672-85

PubMed: ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: ( click the link to review the publication )

J Cell Mol Med, 2015, 10.1111/jcmm.12473

PubMed: 25754106 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.03.014

PubMed: 25850000 ( click the link to review the publication )

J Biol Chem, 2015, 289(46):31950-9

PubMed: 25278019 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(1):125-139

PubMed: 25628925 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):255

PubMed: 25886314 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):241

PubMed: 25884680 ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )
Drug Des Devel Ther, 2015, 9:993-1026

PubMed: 25733817 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(22):6635-47

PubMed: 25252916 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.355

PubMed: 25362851 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2450-62

PubMed: 25053822 ( click the link to review the publication )

Mol Cancer Res, 2014, 10.1158/1541-7786.MCR-14-0153-T

PubMed: 25349289 ( click the link to review the publication )

J Immunol, 2014, 192(8):3958-68

PubMed: 24634494 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(2):372-86

PubMed: 24184209 ( click the link to review the publication )

Ann Surg Oncol, 2014, 21(1):179-88

PubMed: 23907312 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )

Mol Brain, 2014, 7:45

PubMed: 24935155 ( click the link to review the publication )

Transl Oncol, 2014, 10.1016/j.tranon.2014.02.007

PubMed: 24742865 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87281

PubMed: 24489888 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

BMC Biotechnol, 2014, 14:04

PubMed: 24438107 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 454(2):328-34

PubMed: 25450397 ( click the link to review the publication )

Comp Biochem Physiol A , 2014, 168:25-39

PubMed: 24269559 ( click the link to review the publication )

MOL VIS, 2014, 20:1161-1173

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(33):13588-93

PubMed: 23898208 ( click the link to review the publication )

Cancer Res, 2013, 73(17):5449-58

PubMed: 23832664 ( click the link to review the publication )

J Hematol Oncol, 2013, 6:18

PubMed: 23415012 ( click the link to review the publication )
Development, 2013, 140(15):3254-65

PubMed: 23861062 ( click the link to review the publication )

Mol Oncol, 2013, 8(3):469-82

PubMed: 24444656 ( click the link to review the publication )

PLoS One, 2013, 8(8): e72053

PubMed: 23991038 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70804

PubMed: 23936469 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(1):9-17

PubMed: 23946753 ( click the link to review the publication )

Cell Res, 2012, 22(6):1003-21

PubMed: 22430150 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1833(3):652-62

PubMed: 23228564 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(22):7116-26

PubMed: 21976531 ( click the link to review the publication )

J Lipid Res, 2011, 52(9):1617-25

PubMed: 21757781 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Targets

mTOR ^[1]
(HEK293 cells)

~0.1 nM

In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. ^[1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. ^[2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT-29	MmDYR5l1d3SxeHnjJGF{e2G7	NE\IT2EyOCCwTR?=	MkS0O\|IhcA>?	M4LSOmROW09?	NY\uTlFYWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6	NV24fmRNOjR7MEC4O\|M>
HT-29	NFqz[4ZEgXSxdH;4bYMhSXO\|YYm=	MXyxNEBvVQ>?	NYLieGlSPzJiaB?=	M{TYNGROW09?	M33mXHBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=	NYnxXGN1OjR7MEC4O\|M>
HT-29	MXnDfZRwfG:6aXOgRZN{[Xl?	M17lWFExKG6P	Ml[2O\|IhcA>?	NYfuN5ZYTE2VTx?=	NITSbnhRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	NX3GVmVDOjR7MEC4O\|M>
PC3	NFXOenpMcW6jc3WgRZN{[Xl?	NInXO\|EyODBibl2=	NIrjcHcyKGh?	MYfEUXNQ	MlzUVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6=	MYCyNVk4QDZ6Mx?=
PC3	MYTLbY5ie2ViQYPzZZk>	MnvmNVAxKG6P	NX7LNlRqOSCq	NWf4RYdCTE2VTx?=	MXLEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?	NIfxfWkzOTl5OE[4Ny=>
PC3	NHLWNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;tbVMyNjVizszN	NX71[4oyOSCq	MkjxSG1UVw>?	MXfJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN\|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1?	MYCyNVk4QDZ6Mx?=
HEK293	M{LmcmZ2dmO2aX;uJGF{e2G7	M{T3c\|ExOCCwTR?=	M{\rVVghcA>?	MVPEUXNQ	MXHJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1?	Ml\rNlE2Ozl\|MEG=
BT-20	MnfDT4lv[XOnIFHzd4F6	M4T6RVIxKM7:TR?=		Mn7mSG1UVw>?	NH;VOGhFd2W\|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?=	MYGyNVM2OzV3MR?=
U937	NGDp[pdCdnSrYnHjeIVzcWGuIFHzd4F6	NVfKUIx[PTBizszN	MXi0PEBp	NILOR5JFVVOR	MlLWTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy\|	MkHjNlEyPDJzME[=
U937	NVTQflY{SW62aXLhZ5RmemmjbDDBd5NigQ>?	NGXDXGI2OCEQvF2=	NG\obIM1QCCq	MlfYSG1UVw>?	MlXQSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl\|NzDj[Yxtew>?	MmL5NlEyPDJzME[=
U937	NXfoeXJkSW62aXLhZ5RmemmjbDDBd5NigQ>?	NULyRnBmPTBizszN	NFPPWoQ1QCCq	Mke1SG1UVw>?	NEjxWYZFd2W\|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW\|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl\|NzDj[Yxtew>?	MYWyNVE1OjFyNh?=
MCF-7	MkG1RZV1d3CqYXf5JGF{e2G7	NIHBTmM{OCCwTR?=	NVLjNXBbPCCq	MX\EUXNQ	M2\ofGlv\HWlZYOgZZV1d3CqYXf5	MYSyNFAzQDF\|NB?=
U87MG	MW\LbY5ie2ViQYPzZZk>	NXzr[3p2OSEQvF2=	MoD1OkBp	M2jFSWROW09?	M2jK[XBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w	M3qzSFE6QDR6NEC0
U87MG	NYfZeXUyU2mwYYPlJGF{e2G7	MkHJNUDPxE1?	NYjKV2UxPiCq	M4DwdGROW09?	M2PifHBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u	NYfpXG5XOTl6NEi0NFQ>
U87MG	NFS0XWxMcW6jc3WgRZN{[Xl?	NX3m[nIyOSEQvF2=	MVS2JIg>	MV3EUXNQ	MU\Ec4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?	MVuxPVg1QDRyNB?=
U87MG	M{jENmtqdmG\|ZTDBd5NigQ>?	M3\GcFEh\|ryP	MnuyOkBp	MnLJSG1UVw>?	M1vuN2Rw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN\|cwPDZrIIDoc5NxcG:{eXzheIlwdg>?	NIizPIYyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb	NUTxWWZWSXW2b4DoZYd6KEG\|c3H5	Ml;TNE4zKM7:TR?=	NET3dZkzPCCq	NXXle\|JyTE2VTx?=	MlnpTY5lfWOnczDheZRweGijZ4m=	M2r5elE5OzlzOUS5
COS7 cells expressing EGFP-LC3	M{D4emF2fG:yaHHnfUBCe3OjeR?=	MYewMlIh\|ryP	NVLGcWZwOjRiaB?=	NHvKemJFVVOR	M136bWlv\HWlZYOgZZV1d3CqYXf5	MXGxPFM6OTl2OR?=
H4	NH;vS4dHfW6ldHnvckBCe3OjeR?=	MX6wMlIh\|ryP	MlHXNlQhcA>?	MoGySG1UVw>?	M4\qU2lv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM>	MlvONVgxOjR3OES=
HeLa	MoKwSpVv[3Srb36gRZN{[Xl?	MXexNFAhdk1?	NIC4U2o{PiCq	Mn7ySG1UVw>?	NYXQdWR2UW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>?	MkLjNVc2PjN\|OEW=
HeLa	MUTGeY5kfGmxbjDBd5NigQ>?	NI\ZcFcyODBibl2=	NV6xVHB4OzZiaB?=	NGLlTWVFVVOR	NXvpPZVOUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w	MWqxO\|U3OzN6NR?=
HeLa	M37X[mZ2dmO2aX;uJGF{e2G7	NITncZYyODBibl2=	NEfWW3Y{PiCq	MV\EUXNQ	MYTJcoR2[2W\|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36=	M4\mVlE4PTZ\|M{i1
SYF	MVHGeY5kfGmxbjDBd5NigQ>?	MX6xNFAhdk1?	M{j0UVI1KGh?	NVTVUFA6TE2VTx?=	MlTGTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u	NHfMeG0yPzV4M{O4OS=>
SYF	Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXyxNFAhdk1?	MljUNlQhcA>?	NGTxWmZFVVOR	NYrBW25uUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=>	M1nsS\|E4PTZ\|M{i1
HEK293T	MVXBcpRqfmm{YXygRZN{[Xl?	MnLmNUBvVQ>?	MYC0JIQ>	MVPEUXNQ	M4PPWmlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N	NG\QS\|UyPzR6NUWwNS=>
HEK293T	NH\EZ4VCdnSrdnnyZYwhSXO\|YYm=	MkjxNUBvVQ>?	M1\jTFQh\A>?	MlLISG1UVw>?	NFPYVIdKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=>	MVyxO\|Q5PTVyMR?=
PBMC	MoHVSpVv[3Srb36gRZN{[Xl?	NFPaV4QyKG6P	M2nzWFE1KGR?	M33MfGROW09?	M{\tUXJm\HWlZYOgR2NTPSCmZX7zbZR6	MX[xO\|Q5PTVyMR?=
PBMC	NETDdmNHfW6ldHnvckBCe3OjeR?=	MWWxJI5O	MX6xOEBl	NGfnVGRFVVOR	MlfySI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk>	MmLSNVc1QDV3MEG=
HEK293 cells	MnKxT4lv[XOnIFHzd4F6	NHnxS5g2OCCwTR?=	M3vNeVQ2KG2rbh?=	MUjEUXNQ	MkjJTY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR\|UxKG:oIECuNUBvVQ>?	M4TGSVE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc	MkXxSpVv[3Srb36gRZN{[Xl?	NGe4c4cyODBibl2=	MUW0JIg>	NX7jb2VETE2VTx?=	NGfDc45KdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:\|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>?	Mn64NVcyOjh{NkK=
Human mixed lymphocyte	MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVS1JI5O		MofQSG1UVw>?	NITnZmpKSzVyPUGuOkBvVS5?	NIrwXnYyPjF6NUi2OS=>
Lewis rat lymph node cells	NHTldXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XaZ\|Uh\|ryP		Mn[0SG1UVw>?	Ml\OTWM2OD1{Lk[g{txO	NWHLUGUzOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofjNVAhdk1?	Ml7tO\|IhcA>?	NWXwUplFTE2VTx?=	M3\NdmlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2=	NUDDZ5lkOTByMkG5OFg>
MRK-nu-1	NX76TpVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LJR2lEPTB;MD64OFUheE1?	MkDDV2FPT0WU
OCUB-M	NWPxdW9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1z2dGlEPTB;NT6yOEBxVQ>?	NYLMNHlkW0GQR1XS
SF539	NWS4N5NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTFzLk[gdG0>	MYfTRW5ITVJ?
ES4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;RTWM2OD1{MT61JJBO	NV[xfnNmW0GQR1XS
RL95-2	NInnTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYni[pZMUUN3ME2xNFcheE1?	Mn3EV2FPT0WU
LC-2-ad	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHyTWM2OD12MkOgdG0>	NF;4OpRUSU6JRWK=
Daudi	NFznU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfybZlKSzVyPUSzOEBxVQ>?	NULQNJFSW0GQR1XS
NTERA-S-cl-D1	NXmzTIJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHVToN[UUN3ME20OFMheE1?	NV7kZZRPW0GQR1XS
OS-RC-2	NGPaPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjsbI9KSzVyPU[1NkBxVQ>?	NGnsT3NUSU6JRWK=
VA-ES-BJ	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HrO2lEPTB;N{KzJJBO	MoLJV2FPT0WU
GR-ST	M{DZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn74TWM2OD16NE[gdG0>	NXqwXlZDW0GQR1XS
SW872	NE\LU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvzO2VKSzVyPUi0OkBxVQ>?	NEXIW2ZUSU6JRWK=
NOS-1	NUjOc4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTh5MTDwUS=>	MYrTRW5ITVJ?
MC116	NWfuPG5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4G0ZWlEPTB;OUi1JJBO	MlzMV2FPT0WU
NCI-H1355	NHm2dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17rfmlEPTB;MT6wNUBvVQ>?	MUPTRW5ITVJ?
RPMI-8226	NVy5PXo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4X4dGlEPTB;MT6xPUBvVQ>?	MmHPV2FPT0WU
TE-15	M1PmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnLd3VKSzVyPUGuN\|Yhdk1?	MmraV2FPT0WU
Ramos-2G6-4C10	NIXZZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3i1eGlEPTB;MT60OkBvVQ>?	NEnqVHJUSU6JRWK=
KU812	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTJwMEGgcm0>	Mmf1V2FPT0WU
EW-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHy0W2NKSzVyPUKuNVchdk1?	MlfhV2FPT0WU
KS-1	M1L0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTJwNEWgcm0>	MoW1V2FPT0WU
SK-LMS-1	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHkXYtKUUN3ME2yMlQ6KG6P	MV\TRW5ITVJ?
TGBC1TKB	NUiyZZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;xTWM2OD1{Lk[5JI5O	NED5PYtUSU6JRWK=
TE-6	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4W0eWlEPTB;Mj63O{BvVQ>?	MXjTRW5ITVJ?
ETK-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWO2e2hVUUN3ME2yMlgzKG6P	NWjudJZkW0GQR1XS
BE-13	NU\LUotrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTJwOUmgcm0>	MVjTRW5ITVJ?
A3-KAW	M1zkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTJwOUmgcm0>	NIX3PXdUSU6JRWK=
TE-10	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTmWVFbUUN3ME2zMlMhdk1?	MWjTRW5ITVJ?
DOHH-2	MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPDTWM2OD1\|LkO1JI5O	NH7mfm9USU6JRWK=
ES6	NX;nfVdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3W1UGlEPTB;Mz60N{BvVQ>?	Mn\3V2FPT0WU
OPM-2	NWTQe3hwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zLXmlEPTB;ND6xOUBvVQ>?	MUfTRW5ITVJ?
SH-4	M1uzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPS[3V6UUN3ME20MlM1KG6P	MVfTRW5ITVJ?
NB13	NEflRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vNbWlEPTB;ND6zOkBvVQ>?	MWTTRW5ITVJ?
HUTU-80	NETEWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVryPHI4UUN3ME20MlQzKG6P	MUTTRW5ITVJ?
CCRF-CEM	NUfweJpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEL1[lFKSzVyPUSuPVQhdk1?	NYjzR4NOW0GQR1XS
TGBC24TKB	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlqyTWM2OD13LkWxJI5O	NGrlR3FUSU6JRWK=
697	M1\kZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTZwMkigcm0>	NX;1fmo1W0GQR1XS
J-RT3-T3-5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rtT2lEPTB;Nj60OkBvVQ>?	MYPTRW5ITVJ?
KALS-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXNTWM2OD14LkW2JI5O	Ml:0V2FPT0WU
no-10	M3zJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PZ[mlEPTB;Nz6yPUBvVQ>?	NHHYNm5USU6JRWK=
SK-NEP-1	MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvqTWM2OD16Lke5JI5O	MYjTRW5ITVJ?
L-540	NWHiSJp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLCR\|BDUUN3ME2xNE41OiCwTR?=	MUHTRW5ITVJ?
JiyoyeP-2003	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDvUIJiUUN3ME2xNE46PCCwTR?=	MVnTRW5ITVJ?
HH	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1WxNWlEPTB;MUGuN\|khdk1?	M2nj[HNCVkeHUh?=
SR	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\FTWM2OD1zMT60OUBvVQ>?	NUDXSm9VW0GQR1XS
QIMR-WIL	NUnO[Y9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTFzLki1JI5O	Mk\wV2FPT0WU
A4-Fuk	NYLV[Wc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7wbFVJUUN3ME2xN{4yOiCwTR?=	NE\WNpBUSU6JRWK=
CESS	NEjrRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTF\|LkGzJI5O	M12wc3NCVkeHUh?=
KE-37	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnHWGdKSzVyPUG2MlA4KG6P	MUDTRW5ITVJ?
SK-UT-1	M4ftd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTF4LkixJI5O	NYLCVGdjW0GQR1XS
SIG-M5	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGf6SndKSzVyPUG3MlI2KG6P	NX:4VJl4W0GQR1XS
HT	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;XO2lQUUN3ME2xO{43KG6P	M4jrOHNCVkeHUh?=
DEL	M3T4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPVd4xKSzVyPUG3Mlk6KG6P	NXXYfZVxW0GQR1XS
SK-PN-DW	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3GyeGlEPTB;MkCuNlMhdk1?	M37QR3NCVkeHUh?=
RPMI-8402	M4T6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTJzLke3JI5O	NIX5PYxUSU6JRWK=
RPMI-6666	M{fRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\vTWlEPTB;MkSuOFIhdk1?	NYC1R\|BmW0GQR1XS
NCI-H720	NXHMTnM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TUfGlEPTB;MkWuOFEhdk1?	M1\rTHNCVkeHUh?=
EW-16	NGriW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fs[2lEPTB;Mk[uPFchdk1?	M3XHTHNCVkeHUh?=
BL-70	NYfWZXBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfXTWM2OD1{OD6zPEBvVQ>?	NY\QW\|VRW0GQR1XS
SF126	Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LCb2lEPTB;M{CuN\|ghdk1?	MYHTRW5ITVJ?
BC-1	MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\lbFI6UUN3ME2zNU4zPiCwTR?=	MmDGV2FPT0WU
MHH-PREB-1	M2fVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWL1VnZNUUN3ME2zNk41PCCwTR?=	M3rNUHNCVkeHUh?=
A101D	NWfyR2VbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XVNWlEPTB;M{KuOlIhdk1?	MnjVV2FPT0WU
NMC-G1	MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PxSmlEPTB;M{OuOlchdk1?	M1\jU3NCVkeHUh?=
LB1047-RCC	NEHsNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGn2e5RKSzVyPUO0MlY6KG6P	MmTaV2FPT0WU
EM-2	M{\od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTN6LkWzJI5O	MoWzV2FPT0WU
COLO-684	MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnsOpdHUUN3ME2zPU45KG6P	NF\pRVdUSU6JRWK=
Becker	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2L6d2lEPTB;NEGuNFUhdk1?	NVz4[Fg4W0GQR1XS
BL-41	NFPoO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4G2PWlEPTB;NEOuOlYhdk1?	NFLpcYRUSU6JRWK=
MDA-MB-134-VI	NXXQemRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTR2LkCyJI5O	NFfJNoxUSU6JRWK=
L-363	NXnXTm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Lte2lEPTB;NESuO\|Mhdk1?	NEL2XHFUSU6JRWK=
ECC4	MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DDWGlEPTB;NESuO\|ghdk1?	MX3TRW5ITVJ?
A388	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTR2LkiyJI5O	Mlm1V2FPT0WU
HEL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13PSGlEPTB;NEmuO\|khdk1?	M{PMfHNCVkeHUh?=
RKO	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzBSJJKSzVyPUWwMlI6KG6P	NGmzdnFUSU6JRWK=
KINGS-1	MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknnTWM2OD13MT61OUBvVQ>?	NHPCU2pUSU6JRWK=
EB-3	MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTV{Lk[3JI5O	NUj5eG9IW0GQR1XS
ARH-77	NVvHRmNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXhfnVKSzVyPUWyMlghdk1?	M2XUOXNCVkeHUh?=
GCIY	NIfrV\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGS0bZlKSzVyPUWzMlQ3KG6P	NUXC[41wW0GQR1XS
NCI-H1304	NVLTZ2ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTV5LkKyJI5O	MkDiV2FPT0WU
KARPAS-299	NVzUWZZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETR[4ZKSzVyPU[xMlgzKG6P	M1rxVnNCVkeHUh?=
IA-LM	NVPYTppHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3y2S2lEPTB;NkiuNVMhdk1?	NE\Se5VUSU6JRWK=
GI-1	Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zoTGlEPTB;N{CuN\|khdk1?	NWHWUJllW0GQR1XS
TE-11	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfSTWM2OD15Nz6xO{BvVQ>?	MWXTRW5ITVJ?
LS-411N	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW[2U5REUUN3ME23O{42PyCwTR?=	M2PxW3NCVkeHUh?=
no-11	NHPN[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfpT5pKSzVyPUizMlI1KG6P	NVq3NWg6W0GQR1XS
MV-4-11	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;WVlRYUUN3ME24N{44OyCwTR?=	MYfTRW5ITVJ?
BV-173	NHT3NnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2eybGlEPTB;OEOuPVchdk1?	M4HxZnNCVkeHUh?=
CMK	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUD1O29MUUN3ME24OE4yPiCwTR?=	Mm\1V2FPT0WU
LC4-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjoRm1KSzVyPUi2MlczKG6P	MXPTRW5ITVJ?
COR-L279	NIS4[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHRTHVNUUN3ME24O{4zPSCwTR?=	M3TnW3NCVkeHUh?=
NCI-H209	NU\rdJc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzCPYxJUUN3ME24O{41OSCwTR?=	MXLTRW5ITVJ?
Raji	NFTDfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4n1S2lEPTB;OEmuO\|Ihdk1?	NHLiPYpUSU6JRWK=
LB996-RCC	MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvycJBZUUN3ME25N{41OyCwTR?=	M3Poc3NCVkeHUh?=
NCI-H526	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEewPZJKSzVyPUmzMlU6KG6P	M{PRbXNCVkeHUh?=
KGN	M2nQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTafGRsUUN3ME25Ok4zQSCwTR?=	NYS2OlZCW0GQR1XS
MOLT-4	NHvme2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4i1[mlEPTB;OU[uO\|khdk1?	M3XNZXNCVkeHUh?=
PF-382	NUHwUpY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\ORXVKSzVyPUm2Mlc6KG6P	M{DLfnNCVkeHUh?=
BC-3	NW\ZeHB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX60cJJKUUN3ME25PU4yQCCwTR?=	NVjRUmZGW0GQR1XS
KARPAS-422	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoG4TWM2OD1zMEKuNFkhdk1?	NEjXZWlUSU6JRWK=
SBC-1	M1\ncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTuTWM2OD1zMEeuO\|Uhdk1?	NXzHcIU{W0GQR1XS
LC-1F	M1HXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEK1O29KSzVyPUGwPE4xPSCwTR?=	NFXNeYJUSU6JRWK=
GB-1	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzXTWM2OD1zMEmuNFIhdk1?	Mn[yV2FPT0WU
SNB75	NWHhdWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTFzOT62PUBvVQ>?	MmnOV2FPT0WU
BB65-RCC	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nkTWlEPTB;MUG5Mlk{KG6P	NFvnOYtUSU6JRWK=
NCI-N87	NEnJSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jGVmlEPTB;MUKxMlk5KG6P	NIXU[IhUSU6JRWK=
IST-MEL1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{C1bWlEPTB;MUKyMlM5KG6P	NGXkTmpUSU6JRWK=
HOP-62	NU\MZZI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTF{Nj64PUBvVQ>?	MUjTRW5ITVJ?
ACN	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTF2Nj63OUBvVQ>?	M4HrR3NCVkeHUh?=
DMS-114	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;sdGlEPTB;MUWwMlY4KG6P	MmnMV2FPT0WU
MLMA	Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{[xOmlEPTB;MUW5Mlg5KG6P	NGKwfpZUSU6JRWK=
HT-144	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;ZOZhKSzVyPUG2OU41OyCwTR?=	NHHUfoZUSU6JRWK=
C2BBe1	M3\6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITldmhKSzVyPUG2O{44PiCwTR?=	NGfJ[ZdUSU6JRWK=
L-428	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUGxSW52UUN3ME2xO\|cvPyCwTR?=	NV3qeIpiW0GQR1XS
DU-4475	M1jEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTF6Nz62PEBvVQ>?	NHPuNZJUSU6JRWK=
CP67-MEL	NUj0enRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlyyTWM2OD1zOUmuN\|ghdk1?	NHXl[GpUSU6JRWK=
MEG-01	MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4i3VWlEPTB;MkCxMlk3KG6P	NHfybYNUSU6JRWK=
IST-SL2	NUHvbFdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHrVndpUUN3ME2yNFgvPjNibl2=	NYXtRnpWW0GQR1XS
ES8	NV7VW5I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjIRlNXUUN3ME2yNlUvQTRibl2=	NGHsU3pUSU6JRWK=
COLO-800	NUX1fFhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTJ\|NT6yPEBvVQ>?	M1\QfHNCVkeHUh?=
MFH-ino	NVm4PHE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzGbpNKSzVyPUKzOU45PCCwTR?=	MXTTRW5ITVJ?
OVCAR-4	NEG4codIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\RU4NQUUN3ME2yN\|cvOjRibl2=	M{D6SXNCVkeHUh?=
PSN1	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XIc2lEPTB;MkSyMlcyKG6P	NXi1VngyW0GQR1XS
EW-12	MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3iNWJ5UUN3ME2yOFMvOSCwTR?=	NFzBc2lUSU6JRWK=
HCC1599	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJ4MT60O{BvVQ>?	NEfaN5RUSU6JRWK=
SJSA-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFL0dXpKSzVyPUK3NU41PiCwTR?=	M4ftb3NCVkeHUh?=
ST486	MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jHRWlEPTB;Mkm2MlE1KG6P	M1W1fnNCVkeHUh?=
NOMO-1	M{TVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorPTWM2OD1\|MECuNlEhdk1?	M124[XNCVkeHUh?=
MN-60	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHnTWM2OD1\|MEWuN\|Ihdk1?	M3TSRXNCVkeHUh?=
HCC1187	NVfudYZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHlTWM2OD1\|MEeuNlUhdk1?	M2jX[nNCVkeHUh?=
SW982	NWPySldKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTNzND63OUBvVQ>?	MkTRV2FPT0WU
LB647-SCLC	NX\iOmVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\Vd2lEPTB;M{K4MlcyKG6P	NGXiVGZUSU6JRWK=
HC-1	M3jnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnUcXZKSzVyPUOzOU42KG6P	NUXuWIFrW0GQR1XS
EHEB	NY\kVY8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTN\|Nz61NkBvVQ>?	NXrHNXo6W0GQR1XS
TUR	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnoTWM2OD1\|NkOuPVUhdk1?	M3;RPXNCVkeHUh?=
LU-139	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjBTWM2OD1\|N{iuNFIhdk1?	MVnTRW5ITVJ?
NB1	M13MfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnzTWM2OD1\|OESuOFUhdk1?	NYTacplxW0GQR1XS
BB30-HNC	Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLyVGRKSzVyPUO4PE4{OiCwTR?=	M2foNXNCVkeHUh?=
HAL-01	MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnj2TWM2OD1\|OEmuNlYhdk1?	NF34c\|VUSU6JRWK=
K5	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3f4SmlEPTB;NEGxMlM4KG6P	NEPHNYlUSU6JRWK=
MZ2-MEL	MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTRzMz62OEBvVQ>?	MY\TRW5ITVJ?
RXF393	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Pt[mlEPTB;NEG2MlQ2KG6P	Mm\PV2FPT0WU
NCI-H1648	NXr1WFJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTRzNz61N{BvVQ>?	MXXTRW5ITVJ?
TE-12	M4r2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13iXmlEPTB;NEO0MlI3KG6P	NE\sc4VUSU6JRWK=
EoL-1-	M4KzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTR\|Nz65PEBvVQ>?	M3nkZ3NCVkeHUh?=
JAR	NXj3SldNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3tVZFKSzVyPUSzPE43OiCwTR?=	MnvVV2FPT0WU
DSH1	NVnCZXR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvCTWM2OD12NUiuPVEhdk1?	MWfTRW5ITVJ?
NCI-H187	NEnwWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYK1b3R7UUN3ME20OlIvQDFibl2=	NUDsfol2W0GQR1XS
HCE-4	Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTR5Nz62OkBvVQ>?	M{O1UHNCVkeHUh?=
8-MG-BA	NGrh[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfE[5VKSzVyPUW4NU42OiCwTR?=	NV76OGRKW0GQR1XS
KLE	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzG[nFuUUN3ME21PFUvOiCwTR?=	NVPuNY9EW0GQR1XS
KNS-42	NVjxSIk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTV6Nj64NUBvVQ>?	M2TCVnNCVkeHUh?=
MSTO-211H	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTZyOT63OEBvVQ>?	M3\vRXNCVkeHUh?=
GDM-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\ZZYpKSzVyPU[xOE4xQSCwTR?=	NGLMOo5USU6JRWK=
TE-1	NVjoeY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnznTWM2OD14NE[uNVIhdk1?	NH3rUYJUSU6JRWK=
BT-474	MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTZ2Nz6wOkBvVQ>?	NWjle41tW0GQR1XS
KARPAS-45	MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWGxfXRGUUN3ME22OFcvPiCwTR?=	NIjvNZRUSU6JRWK=
MOLT-16	MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDvXZNKSzVyPU[0O{46OyCwTR?=	NUjhb2s{W0GQR1XS
KURAMOCHI	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVf3[JpEUUN3ME22OVcvPTFibl2=	MkjqV2FPT0WU
K-562	NXTmV2ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLuTWM2OD14NkmuOVEhdk1?	M4HVXHNCVkeHUh?=
EKVX	NUfJPFhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3H0R2lEPTB;NkeyMlcyKG6P	M33ZW3NCVkeHUh?=
GAK	M3XWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3K4fWlEPTB;Nke1MlMhdk1?	NYn3S3d4W0GQR1XS
NCI-SNU-5	M1XYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1L4e2lEPTB;NkmwMlAyKG6P	NVj6ZWFzW0GQR1XS
NCI-H2126	NY\WfpBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDITWM2OD15Mk[uPFchdk1?	NYLyRXRoW0GQR1XS
CTV-1	Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITmZ3RKSzVyPUe0OE46KG6P	MVfTRW5ITVJ?
SW962	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml:3TWM2OD15NEiuOFQhdk1?	Mn25V2FPT0WU
MONO-MAC-6	NG[y[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;4TWM2OD15NU[uPVMhdk1?	NXvjWXhxW0GQR1XS
NCI-H748	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXP6PIFlUUN3ME23OVgvQTlibl2=	MnS1V2FPT0WU
NCI-H524	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfOcYdKSzVyPUe4NE44OyCwTR?=	M3W0NXNCVkeHUh?=
LS-123	NYP2TpJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3rTWM2OD15OUWuOlkhdk1?	NVrZ[Vh3W0GQR1XS
NB7	M1\Dd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIf2TYRKSzVyPUixOE4yPCCwTR?=	M3HkOXNCVkeHUh?=
LS-1034	NYq1O4Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTh{OD65PEBvVQ>?	NWTV[VRkW0GQR1XS
TE-5	NW[5XIdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHJVnFKSzVyPUi4N{42PiCwTR?=	NHL0UY1USU6JRWK=
A704	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3vTWM2OD16OUmuNVUhdk1?	MmnZV2FPT0WU
TK10	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTlzNj6wN{BvVQ>?	NFnVbpZUSU6JRWK=
NCI-H345	NHzNc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF22XW5KSzVyPUm0N{4zOiCwTR?=	MU\TRW5ITVJ?
CGTH-W-1	MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTl2OD6xN{BvVQ>?	MVTTRW5ITVJ?
NCI-H510A	MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTl6NT6xNkBvVQ>?	NULUXnhTW0GQR1XS
NCI-H1963	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFwMEOyPVIh\|ryP	NUP1eYZKW0GQR1XS
SCC-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DFR2lEPTB;MT6wN\|QyPCEQvF2=	MkTiV2FPT0WU
EW-11	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDUbGpKSzVyPUGuNFg4PDNizszN	M3f0bnNCVkeHUh?=
CPC-N	NXiz[ZRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzYc5JKSzVyPUGuNFg5KM7:TR?=	NILLOpFUSU6JRWK=
NCI-H1417	NFHSVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LxTWlEPTB;MT6xNlI3KM7:TR?=	NUnaWXF4W0GQR1XS
DG-75	MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfoVGFKSzVyPUGuNVYzQDVizszN	MlvrV2FPT0WU
HD-MY-Z	NUO4bpppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2r0T2lEPTB;MT6xOlQyPiEQvF2=	NVfUOnFOW0GQR1XS
ATN-1	NE\Td5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrERWp3UUN3ME2xMlI3OjB7IN88US=>	NXfUcpdbW0GQR1XS
KM-H2	NVjJcJFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2i2[WlEPTB;MT6yOlQxQCEQvF2=	NX\LcXB2W0GQR1XS
NCI-H2081	NYG1[WFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\MNXBOUUN3ME2xMlI3PjN5IN88US=>	NIKzWXhUSU6JRWK=
HL-60	Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DXTWlEPTB;MT6yOlk2QSEQvF2=	MXTTRW5ITVJ?
DB	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3z6XGlEPTB;MT6yO\|I1OiEQvF2=	Mo\6V2FPT0WU
NCI-H1522	NHPMeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fjXmlEPTB;MT6yPFg5PyEQvF2=	NWrvNJRVW0GQR1XS
AM-38	NWj1WVBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTFwM{C3NkDPxE1?	NYS2bHJbW0GQR1XS
NCI-H446	M2TvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1y3ZWlEPTB;MT6zNlEzOSEQvF2=	MUTTRW5ITVJ?
SU-DHL-1	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLhbG4yUUN3ME2xMlMzQDBzIN88US=>	M4jqO3NCVkeHUh?=
NH-12	NFPR[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mny0TWM2OD1zLkO2N\|c1KM7:TR?=	MUHTRW5ITVJ?
DMS-79	NYL1Rmh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\hTWM2OD1zLkO2PFY3KM7:TR?=	NYP5PZVjW0GQR1XS
NCI-H716	MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TpeWlEPTB;MT6zPFk5PiEQvF2=	MXLTRW5ITVJ?
ML-2	NIftbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPScGdKSzVyPUGuOFE2OjlizszN	NHTHdWRUSU6JRWK=
NB10	M3\rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnFTWM2OD1zLkS2OlMzKM7:TR?=	M2nONXNCVkeHUh?=
ONS-76	NEPUe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjzTWM2OD1zLkWzOVY6KM7:TR?=	NIfnW5ZUSU6JRWK=
LOUCY	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\SUXhIUUN3ME2xMlU1PjV5IN88US=>	NXv6XlFjW0GQR1XS
SCLC-21H	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXLPWJKSzVyPUGuOVg2QDJizszN	MoWyV2FPT0WU
TGW	M1\EV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NET1WZJKSzVyPUGuOlM6PzVizszN	MoOwV2FPT0WU
LXF-289	NYG1dYZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTFwN{OyOlgh\|ryP	MYrTRW5ITVJ?
BB49-HNC	NFjhXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7JcVE5UUN3ME2xMlc{PTh4IN88US=>	MUDTRW5ITVJ?
NCI-H747	NGnk[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\nRm1KSzVyPUGuO\|U{PDZizszN	NH72ZnNUSU6JRWK=
LU-165	M4CyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTFwOES5PFYh\|ryP	MUPTRW5ITVJ?
OMC-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHxOVVKSzVyPUGuPVUxPjZizszN	NWDkOmVEW0GQR1XS
RCC10RGB	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1naPWlEPTB;MT65OVgyPyEQvF2=	NH\tfJdUSU6JRWK=
SW684	NVXQeVJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTFwOU[wPVkh\|ryP	MX7TRW5ITVJ?
TE-8	MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJwMEW1OVkh\|ryP	M3Pwe3NCVkeHUh?=
SK-N-DZ	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3Wb2ZKSzVyPUKuNVMzPzRizszN	NHn6fVZUSU6JRWK=
EVSA-T	NXL6cWk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTJwMUezNVUh\|ryP	MXnTRW5ITVJ?
KASUMI-1	NY\nOpFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjZflhKSzVyPUKuNVg5OTVizszN	MlPCV2FPT0WU
NKM-1	NXH1cZp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTJwMkW0O\|Ih\|ryP	MYLTRW5ITVJ?
CAL-148	NFjlbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn2zTWM2OD1{LkOzOlE1KM7:TR?=	NWTjVIRYW0GQR1XS
NCI-H64	M4Lqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmf2TWM2OD1{LkO0NlMzKM7:TR?=	MUDTRW5ITVJ?
KNS-81-FD	NWrjUnZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTyTWM2OD1{LkO2OlIh\|ryP	MUDTRW5ITVJ?
KM12	NVvvU2dvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fEemlEPTB;Mj60NFg{QSEQvF2=	MWnTRW5ITVJ?
SW954	Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3G5emlEPTB;Mj60O\|c4QSEQvF2=	NH:yUWVUSU6JRWK=
NCI-H1395	NF7nWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTJwNUK2OFUh\|ryP	MXvTRW5ITVJ?
DJM-1	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PFRWlEPTB;Mj62NFY{KM7:TR?=	MXvTRW5ITVJ?
COLO-668	NFPLbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDFVW54UUN3ME2yMlgzPjl3IN88US=>	Moq2V2FPT0WU
NCI-H1436	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTJwOEW2NVUh\|ryP	MXzTRW5ITVJ?
LB2241-RCC	M{DRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTJwOE[4N\|kh\|ryP	MofVV2FPT0WU
GT3TKB	NXjsSVF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnpdlhWUUN3ME2yMlg6ODV3IN88US=>	NH[2SJBUSU6JRWK=
COLO-824	M4HId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmToTWM2OD1{Lki5O\|Y5KM7:TR?=	NVLt[ZBjW0GQR1XS
ES1	Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3z[5dKSzVyPUKuPFk5PzlizszN	NHL0UnFUSU6JRWK=
LB771-HNC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzETWM2OD1{LkmwPVQ3KM7:TR?=	NUW5ZXY6W0GQR1XS
GI-ME-N	M1naOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGf4S5dKSzVyPUOuNFA6ODRizszN	Moj4V2FPT0WU
NALM-6	NVS2PFFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTNwMEC5N\|Mh\|ryP	NFX1eWNUSU6JRWK=
LU-134-A	NH3YTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTNwMEW0NlUh\|ryP	NGP6UFJUSU6JRWK=
DMS-153	NUnIOJdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXq4WY5PUUN3ME2zMlA2QDJ2IN88US=>	MYLTRW5ITVJ?
MZ1-PC	M3z5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2juS2lEPTB;Mz6wPVA4QCEQvF2=	MXvTRW5ITVJ?
NCI-H1155	NF3ZZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7idIFKSzVyPUOuNVE3OSEQvF2=	MmXWV2FPT0WU
CAS-1	MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;jc2RKSzVyPUOuNVM4ODdizszN	MU\TRW5ITVJ?
D-502MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFT3PZVKSzVyPUOuNVQ{QSEQvF2=	NXzhdpdUW0GQR1XS
NCI-H2141	NUnBSIgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTNwMUe0OVIh\|ryP	MUfTRW5ITVJ?
NB6	MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTNwMUiyOVkh\|ryP	MUjTRW5ITVJ?
NCCIT	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37kRmlEPTB;Mz6yNVgxQSEQvF2=	MWDTRW5ITVJ?
NB69	NVnBXFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4P0OGlEPTB;Mz6zNVg6OSEQvF2=	MWPTRW5ITVJ?
JVM-2	NHXRUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTNwM{[0N\|Mh\|ryP	M4fJTnNCVkeHUh?=
K052	MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{OzXmlEPTB;Mz6zO\|k3QCEQvF2=	NWHwNZlOW0GQR1XS
HCC2157	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojrTWM2OD1\|LkWzNlI5KM7:TR?=	M3zB[XNCVkeHUh?=
KMOE-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzMcoFoUUN3ME2zMlU1OjR{IN88US=>	MYXTRW5ITVJ?
SF268	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlywTWM2OD1\|LkexOVU1KM7:TR?=	MVrTRW5ITVJ?
CHP-126	M1TkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnHU5FvUUN3ME2zMlc3PDV6IN88US=>	NIjPXmlUSU6JRWK=
CP66-MEL	M3f4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;rTWM2OD1\|Lke5NFk1KM7:TR?=	NGf2d3hUSU6JRWK=
NCI-H69	M135ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTRwMEG5N\|Yh\|ryP	NV7sSHg5W0GQR1XS
A253	M17hU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFq1OoVKSzVyPUSuNFIyODFizszN	MUDTRW5ITVJ?
NB14	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorpTWM2OD12LkGwOFc6KM7:TR?=	NYT0UGViW0GQR1XS
NCI-H1694	NYTzVpI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVGybnY4UUN3ME20MlE{OTF{IN88US=>	NHjSeHNUSU6JRWK=
NCI-H2196	NFS0RVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XlTGlEPTB;ND6xO\|E3QSEQvF2=	NIXSU3dUSU6JRWK=
TE-9	M4nSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDqTJRrUUN3ME20MlE4PTh{IN88US=>	NHPrbWlUSU6JRWK=
D-283MED	NGTHUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\ETWM2OD12LkG4PFQh\|ryP	M2rzZ3NCVkeHUh?=
OCI-AML2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTRwMUm0PFkh\|ryP	NV\weVk5W0GQR1XS
D-263MG	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nhTWlEPTB;ND6yNlk3OSEQvF2=	MYXTRW5ITVJ?
MPP-89	NITYO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37vcmlEPTB;ND6yO\|MxPCEQvF2=	MXzTRW5ITVJ?
LAMA-84	NHL6OG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTRwM{C0NlEh\|ryP	MWHTRW5ITVJ?
LB373-MEL-D	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rHXGlEPTB;ND6zOlc5QSEQvF2=	NGjHNoNUSU6JRWK=
UACC-257	MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWH2[mFwUUN3ME20MlM6PTN2IN88US=>	MmXCV2FPT0WU
MC-CAR	MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2C4VmlEPTB;ND60N\|k6KM7:TR?=	NFXS[nZUSU6JRWK=
COLO-320-HSR	NGrSU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTRwNES0Nlch\|ryP	NV[5bWhjW0GQR1XS
P30-OHK	NITidpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrlTWM2OD12Lk[2OVgyKM7:TR?=	MoLsV2FPT0WU
UACC-812	M3jZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHmcoxKSzVyPUSuOlkyPjFizszN	Mo\EV2FPT0WU
CTB-1	MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3kTZNKSzVyPUSuO\|E2PTVizszN	NWXPN3g{W0GQR1XS
ALL-PO	M3nJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nSdmlEPTB;ND64OFA4PyEQvF2=	NIT4bGZUSU6JRWK=
SK-MEL-2	M3PuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzxZo5KSzVyPUSuPFY6PTVizszN	NUXC[JYxW0GQR1XS
TC-YIK	MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfvSoM3UUN3ME20Mlk4QTR{IN88US=>	MlLGV2FPT0WU
NCI-H1882	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnmPVJyUUN3ME21MlAzODBzIN88US=>	MUXTRW5ITVJ?
MHH-CALL-2	M4XnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojYTWM2OD13LkC1NFQzKM7:TR?=	M3O3W3NCVkeHUh?=
U-87-MG	NYHROG5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV6xbIVEUUN3ME21MlA6PDZ4IN88US=>	M{jiSXNCVkeHUh?=
NCI-H1092	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHNUXBCUUN3ME21MlI3PTV3IN88US=>	NEPzW5JUSU6JRWK=
TE-441-T	NXS0e\|ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\BSmlEPTB;NT6yO\|gzKM7:TR?=	NXi0T3g5W0GQR1XS
SK-MEL-1	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3NTXpKSzVyPUWuNlkxPDRizszN	NYTkeGJbW0GQR1XS
EW-22	M4HCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDCO3I3UUN3ME21MlI6PDZ4IN88US=>	NX7SZ\|NnW0GQR1XS
MZ7-mel	M33LSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7xTG5KSzVyPUWuOFA3QTFizszN	NGrPendUSU6JRWK=
LP-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWS2ZVllUUN3ME21MlQyOjlzIN88US=>	MYPTRW5ITVJ?
NCI-SNU-16	NILtOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{T3[mlEPTB;NT62OFA4PCEQvF2=	MXHTRW5ITVJ?
LU-65	NELxSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1q5T2lEPTB;NT63OlM4OyEQvF2=	NF\RVYRUSU6JRWK=
CW-2	M1y3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\hTWM2OD13Lki1PVU6KM7:TR?=	NU\PWYVUW0GQR1XS
WSU-NHL	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\VTWM2OD13Lkm1NVc1KM7:TR?=	NVHwTnM6W0GQR1XS
IST-MES1	MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUSwPGlWUUN3ME21Mlk2PDR\|IN88US=>	NWTwdFdrW0GQR1XS
U-266	M1viNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTJOJdKSzVyPUWuPVgzODJizszN	NHuxcYNUSU6JRWK=
TALL-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUO0bGRDUUN3ME22MlE1Pjh6IN88US=>	NHXUT5BUSU6JRWK=
Calu-6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmT5TWM2OD14LkG1N\|E3KM7:TR?=	NFL3WHVUSU6JRWK=
MMAC-SF	M2rEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHryV3RKSzVyPU[uNVg2PTZizszN	M4LGZ3NCVkeHUh?=
NCI-H82	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M365SGlEPTB;Nj6yNFQ5QSEQvF2=	NEHDVXVUSU6JRWK=
RS4-11	NXzhXIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnCcZJqUUN3ME22MlI2QDl5IN88US=>	M2H5dXNCVkeHUh?=
SNU-C2B	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkX1TWM2OD14LkSwPVY6KM7:TR?=	MXfTRW5ITVJ?
BOKU	NE\q[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnjZYVKSzVyPU[uOFc2QTdizszN	Ml73V2FPT0WU
C8166	M3jmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDTTWM2OD14LkW1PVEzKM7:TR?=	NFjWSJdUSU6JRWK=
D-247MG	MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTdwMESzOFch\|ryP	NUK1WFFQW0GQR1XS
EW-18	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;MOnNKSzVyPUeuNFczQTJizszN	NG\rbWtUSU6JRWK=
KG-1	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PzTGlEPTB;Nz62Nlc{QCEQvF2=	NYfvbIsyW0GQR1XS
REH	M4LWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkGyTWM2OD15Lk[4NVA6KM7:TR?=	M4j1UnNCVkeHUh?=
U-698-M	M4ToXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rDZ2lEPTB;Nz64OFMyPSEQvF2=	MXnTRW5ITVJ?
KP-N-RT-BM-1	NHLWemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPQTWM2OD15LkmzNFI6KM7:TR?=	NV\qT\|hWW0GQR1XS
MS-1	MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DmPGlEPTB;Nz65OlA1OSEQvF2=	NIfqOHFUSU6JRWK=
SNU-C1	M{K4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTdwOUixPVIh\|ryP	M3nE[XNCVkeHUh?=
SK-MM-2	NILJZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHq5ZVdKSzVyPUiuNlYxPjVizszN	MWLTRW5ITVJ?
LAN-6	MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjNVGNKSzVyPUiuN\|AxODFizszN	M1vTPXNCVkeHUh?=
NEC8	M{DtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\0TWM2OD16LkOwOlkyKM7:TR?=	MWLTRW5ITVJ?
NCI-H1770	NUfaVmRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojaTWM2OD16LkO4NFAzKM7:TR?=	MoTyV2FPT0WU
D-336MG	NXuzOYE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorZTWM2OD16LkSwNVE3KM7:TR?=	MmTFV2FPT0WU
COLO-829	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DZbGlEPTB;OD60PFg4QSEQvF2=	NYfhOmF2W0GQR1XS
LS-513	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRThwNUm1PVkh\|ryP	MX3TRW5ITVJ?
YT	NYXk[\|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\mbZh6UUN3ME24MlYzPDJ5IN88US=>	MUHTRW5ITVJ?
EW-24	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWiyTmpzUUN3ME24Mlc3PTRizszN	M{e4PHNCVkeHUh?=
IST-SL1	NFvIeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRThwOE[1OFMh\|ryP	MUjTRW5ITVJ?
CA46	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XuRmlEPTB;OD65OVA6QCEQvF2=	MoPqV2FPT0WU
NCI-H1838	M4fsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfOSFYzUUN3ME24Mlk5PjB{IN88US=>	MWnTRW5ITVJ?
NCI-H719	M4fJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTlwMkWyO\|kh\|ryP	MmDpV2FPT0WU
HCE-T	NVnQdYo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTlwM{C4OVEh\|ryP	MWXTRW5ITVJ?
A498	M3ux[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;ZfG1KSzVyPUmuN\|YyOjRizszN	NUTDZmY1W0GQR1XS
LB831-BLC	M3;ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTlwN{[1NlEh\|ryP	NY[0WYd4W0GQR1XS
SKM-1	NHi5ZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTlwOEW5OlMh\|ryP	M1\IWnNCVkeHUh?=
THP-1	M3Wzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fXUWlEPTB;OT65OlkyQCEQvF2=	M{W3[XNCVkeHUh?=
SHP-77	MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vqfWlEPTB;MUCuOFA4KM7:TR?=	NIPNUo1USU6JRWK=
EW-3	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTFyLk[yPFkh\|ryP	MoHGV2FPT0WU
KY821	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHwN5JEUUN3ME2xNE44PjNizszN	MorPV2FPT0WU
NCI-SNU-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLGeIdKSzVyPUGxMlAzOTdizszN	M{H5b3NCVkeHUh?=
HCC2218	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPlW3FzUUN3ME2xNU4{QTh4IN88US=>	MVTTRW5ITVJ?
IM-9	M1PtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTFzLkWxNFYh\|ryP	NVO2bHAxW0GQR1XS
NCI-H889	NY\FT2ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfQPJZyUUN3ME2xNU42OzF\|IN88US=>	NVjkWZloW0GQR1XS
HDLM-2	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3L4W2lEPTB;MUKuOFE2QSEQvF2=	MV\TRW5ITVJ?
LB2518-MEL	M13HSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPkS2hKSzVyPUGyMlY5OTVizszN	MmfLV2FPT0WU
NCI-H23	MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PkZ2lEPTB;MUOuNlQzPSEQvF2=	NYXuTXd5W0GQR1XS
NB17	NH7BbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3tVmtKSzVyPUGzMlQ2PzlizszN	MoLWV2FPT0WU
NCI-H322M	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTF2LkSwOlgh\|ryP	NGjxPGlUSU6JRWK=
SUP-T1	NHXveXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoW4TWM2OD1zND60NVMh\|ryP	M2\oOXNCVkeHUh?=
ES3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorTTWM2OD1zNT6wO\|A{KM7:TR?=	MUPTRW5ITVJ?
ES5	M{H2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7UOmhKSzVyPUG1MlA4QDdizszN	NEj6PJBUSU6JRWK=
NCI-H1650	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;aTWM2OD1zNT60PVc6KM7:TR?=	MXHTRW5ITVJ?
NCI-H226	Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXQR45KSzVyPUG1Mlg4PjhizszN	MljhV2FPT0WU
COR-L88	NFfafHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTF4LkOxOEDPxE1?	NUXVSVI6W0GQR1XS
SCC-15	Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonJTWM2OD1zNj6zPFY6KM7:TR?=	MXjTRW5ITVJ?
GOTO	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\KWINKSzVyPUG2MlQ4QTNizszN	NGHOZmJUSU6JRWK=
SIMA	NI\sRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vTTmlEPTB;MU[uOFgxOiEQvF2=	NV;Xfm93W0GQR1XS
NCI-H1299	M{TOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTF5LkG1PVEh\|ryP	NInP[lNUSU6JRWK=
NCI-H1581	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLPbIpKSzVyPUG3MlQzOTlizszN	M2r4ZXNCVkeHUh?=
MHH-NB-11	NV7CTY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETQflFKSzVyPUG3Mlk3QDNizszN	NHjSW\|hUSU6JRWK=
MFM-223	NF3IOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTF6LkC1N\|gh\|ryP	M{\RdHNCVkeHUh?=
ES7	M2KwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HiU2lEPTB;MUiuOVQ{OSEQvF2=	MYnTRW5ITVJ?
JVM-3	M1\XTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTsTWM2OD1zOD63NVch\|ryP	M2P5cXNCVkeHUh?=
RL	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjKSHBKSzVyPUKwMlM5QCEQvF2=	NHfCSo1USU6JRWK=
EC-GI-10	NIfiWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTJzLkKwOFEh\|ryP	MVXTRW5ITVJ?
LNCaP-Clone-FGC	NVXYS\|M3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Wyc2lEPTB;MkGuOlc3QCEQvF2=	MlvGV2FPT0WU
IMR-5	M37JXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rZPWlEPTB;MkGuPFQ6PCEQvF2=	NXXLcpRKW0GQR1XS
KP-N-YS	NYS2WHM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HueGlEPTB;MkGuPFc2KM7:TR?=	M1i5TXNCVkeHUh?=
Mo-T	NEC4RnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17SfGlEPTB;MkKuNlE5PSEQvF2=	MlT2V2FPT0WU
NCI-H128	Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojjTWM2OD1{Mz61PFU{KM7:TR?=	M3zkeHNCVkeHUh?=
RH-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfL[4NKSzVyPUKzMlc5PjZizszN	Mnv2V2FPT0WU
NCI-H2171	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLhZXJWUUN3ME2yOE4zPDh3IN88US=>	M2rmfHNCVkeHUh?=
RPMI-8866	NHrLNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTITWM2OD1{Nj63OFIh\|ryP	NGLJVYpUSU6JRWK=
SK-N-FI	NFziemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHf4cGhKSzVyPUK3MlM5OTFizszN	MmG2V2FPT0WU
LOXIMVI	M{HRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfwWoZVUUN3ME2yO{45ODVzIN88US=>	NUW2bWx4W0GQR1XS
P31-FUJ	MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\6SmNKSzVyPUOxMlU{PzRizszN	Mn:xV2FPT0WU
KMS-12-PE	MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;kTWM2OD12OT61N\|AzKM7:TR?=	NVTqWlZwW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR(S2448)/mTOR; PubMed: 23991038 PLoS One MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.	23991038
Growth inhibition assay	Cell proliferation; PubMed: 30393233 Biosci Rep (A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.	30393233
Histomorphology	Haematoxylin & Eosin; PubMed: 28418837 Oncotarget Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.	28418837
Immunofluorescence	NeuN; PubMed: 28418837 Oncotarget Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown. p62/Beclin; PubMed: 28819214 Sci Rep (C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody.	28418837 28819214
ELISA	Type III collagen/Fibronectin; PubMed: 23364979 Yonsei Med J (A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.	23364979

In vivo

Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. ^[4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. ^[5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. ^[6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. ^[7]

Protocol

Kinase Assay: ^[1]	+ Expand Immunoblotting for the mTOR kinase assay: HEK293 cells are plated at 2-2.5×10⁵ cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research: ^[3]	+ Expand Cell lines: U87-MG, T98G, and U373-MG Concentrations: Dissolved in DMSO, final concentrations ~25 μM Incubation Time: 72 hours Method: Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope. (Only for Reference)
Animal Research: ^[7]	+ Expand Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O) Dosages: ~4 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	20 mg/mL (21.87 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Rapamycin (Sirolimus) SDF

Molecular Weight	914.18
Formula	C₅₁H₇₉NO₁₃
CAS No.	53123-88-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	AY 22989，NSC-2260804

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03866681	Not yet recruiting	Paroxysmal Nocturnal Hemoglobinuria	Peking Union Medical College Hospital	April 1 2019	Phase 4
NCT03454724	Not yet recruiting	Coronary Artery Disease	Meril Life Sciences Pvt. Ltd.	April 1 2019	Not Applicable
NCT03877809	Not yet recruiting	Beta-Thalassemia	Rare Partners srl Impresa Sociale\|Università degli Studi di Ferrara	April 1 2019	Phase 2
NCT03866681	Not yet recruiting	Paroxysmal Nocturnal Hemoglobinuria	Peking Union Medical College Hospital	April 1 2019	Phase 4
NCT03454724	Not yet recruiting	Coronary Artery Disease	Meril Life Sciences Pvt. Ltd.	April 1 2019	Not Applicable
NCT03877809	Not yet recruiting	Beta-Thalassemia	Rare Partners srl Impresa Sociale\|Università degli Studi di Ferrara	April 1 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Pan mTOR inhibitor

KU-0063794 : mTORC1 and mTORC2, IC50=~10 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.
Classic mTOR Inhibitor

BEZ235 (NVP-BEZ235, Dactolisib) : Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Related mTOR Products4

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Rapamycin (Sirolimus)

Cited by 130 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Rapamycin (Sirolimus) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Rapamycin (Sirolimus)

Cited by 130 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Rapamycin (Sirolimus) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)